Loading...
•
Dec 31, 2025
Vir Q4 2025 Earnings Report
Vir Biotechnology reported higher Q4 2025 revenue driven by a Norgine license agreement and a narrowed net loss compared to the prior year period.
Key Takeaways
For Q4 2025, Vir reported total revenue of 64070000 primarily from license revenue, with a net loss of 42923000, reflecting reduced operating expenses year over year and a strengthened cash position of 781600000 in cash and investments.
Total revenue increased to 64070000 from 12374000 year over year.
License and collaboration revenue was 63760000 in Q4 2025.
R&D expenses declined to 88349000 from 106083000 year over year.
Net loss narrowed to 42923000 compared to 104589000 in Q4 2024.
Revenue by Segment
Forward Guidance
Vir expects its cash, cash equivalents and investments to fund operations into the second quarter of 2028 based on current operating plans and anticipated collaboration effects.
Positive Outlook
- Cash, cash equivalents and investments totaled 781600000 as of December 31, 2025.
- Company expects cash runway into the second quarter of 2028.
- Collaboration with Astellas expected to support financial position.
- Initial 64300000 payment received from Norgine in Q4 2025.
- Operating expenses declined year over year in Q4 2025.
Challenges Ahead
- Net loss of 42923000 in Q4 2025.
- Loss from operations of 47921000 in Q4 2025.
- R&D expenses remained high at 88349000 in Q4 2025.
- Decline of approximately 29100000 in cash and investments during Q4 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...